EyePoint Pharmaceuticals (EYPT) Income from Continuing Operations: 2010-2018
Historic Income from Continuing Operations for EyePoint Pharmaceuticals (EYPT) over the last 9 years, with Jun 2018 value amounting to -$53.2 million.
- EyePoint Pharmaceuticals' Income from Continuing Operations fell 139.24% to -$14.4 million in Q3 2018 from the same period last year, while for Sep 2018 it was -$34.6 million, marking a year-over-year decrease of 99.88%. This contributed to the annual value of -$53.2 million for FY2018, which is 187.64% down from last year.
- According to the latest figures from FY2018, EyePoint Pharmaceuticals' Income from Continuing Operations is -$53.2 million, which was down 187.64% from -$18.5 million recorded in FY2017.
- EyePoint Pharmaceuticals' 5-year Income from Continuing Operations high stood at $8.0 million for FY2015, and its period low was -$53.2 million during FY2018.
- Its 3-year average for Income from Continuing Operations is -$31.1 million, with a median of -$21.5 million in 2016.
- Per our database at Business Quant, EyePoint Pharmaceuticals' Income from Continuing Operations soared by 160.08% in 2015 and then crashed by 368.53% in 2016.
- Over the past 5 years, EyePoint Pharmaceuticals' Income from Continuing Operations (Yearly) stood at -$13.4 million in 2014, then surged by 160.08% to $8.0 million in 2015, then plummeted by 368.53% to -$21.5 million in 2016, then rose by 14.21% to -$18.5 million in 2017, then crashed by 187.64% to -$53.2 million in 2018.